For 2010 information on Risk Evaluation and Mitigation Strategy (REMS) please see the FDA Archive Safety AnnouncementAdditional Information for PatientsAdditional Information for Healthcare ProfessionalsData SummaryReferences Safety […]

(en Español) Safety AnnouncementAdditional Information for PatientsAdditional Information for Healthcare ProfessionalsData Summary  Safety Announcement [3-28-2012] The U.S. Food and Drug Administration (FDA) is clarifying dosing and […]

(en Español) Safety Announcement [4-10-2012] The U.S. Food and Drug Administration (FDA) has completed its review of recent observational (epidemiologic) studies regarding the risk of blood […]

(en Español) Safety AnnouncementAdditional Information for PatientsAdditional Information for Healthcare ProfessionalsData Summary  Safety Announcement [4-20-2012] The U.S. Food and Drug Administration (FDA) is warning of possible […]

(en Español) Safety Announcement [4-26-2012] The U.S. Food and Drug Administration (FDA) is notifying the public that co-administration of Victrelis (boceprevir), a hepatitis C virus (HCV) […]

(en Español) Safety AnnouncementAdditional Information for PatientsAdditional Information for Healthcare Professionals Data Summary   Safety Announcement Facts about Revlimid (lenalidomide) Prescription medicine approved in combination with dexamethasone to […]

(en Español) Safety AnnouncementAdditional Information for Patients and CaregiversAdditional Information for Health Care ProfessionalsData Summary Safety Announcement [6-26-2012] The U.S. Food and Drug Administration (FDA) is […]

Safety AnnouncementAdditional Information for PatientsAdditional Information for Healthcare ProfessionalsData Summary Safety Announcement [06-29-2012] The U.S. Food and Drug Administration (FDA) is informing healthcare professionals and the […]